Preliminary unaudited Q4 and Full Year 2025 net Attruby®product revenue of $146.0 million and $362.4 million, respectively ...

Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...

Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

The outlook for transthyretin amyloidosis (ATTR amyloidosis) depends on factors such as your type, affected organs, and how early you start treatment. Average survival rates differ by type: familial ...

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

Amyloidosis happens when amyloid proteins build up and form deposits that damage organs and tissues, causing symptoms like swelling, anemia, and weight loss. A doctor can diagnose it with lab work, ...

News-driven FX Trading: How to Trade Events Like the FOMC, CPI, and NFP ...